Linqi Zhang

List of Publications by Citations

99 papers	9,132 citations	33 h-index	95 g-index
113 ext. papers	12,123 ext. citations	14.1 avg, IF	6.51 L-index

#	Paper	IF	Citations
99	Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*, **2020**, 581, 215-220	50.4	2961
98	Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*, **2020**, 584, 115-119	50.4	982
97	The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. *Cell*, **2020**, 182, 1284-1294.e9	38.6	899
96	Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2020**, 324, 460-470	27.4	755
95	Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. *Cell Research*, **2013**, 23, 986-93	24.7	459
94	The changing face of HIV in China. *Nature*, **2008**, 455, 609-11	50.4	213
93	Potent human neutralizing antibodies elicited by SARS-CoV-2 infection		211
92	SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. *Cell*, **2021**, 184, 2362-2371.e9	38.6	197
91	HIV-1 subtype and second-receptor use. *Nature*, **1996**, 383, 768	50.4	173
90	Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. *Journal of Biological Chemistry*, **2008**, 283, 11126-34	5.4	169
89	Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. *Science Translational Medicine*, **2014**, 6, 234ra59	17.5	165
88	Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. *Journal of Medical Virology*, **2006**, 78, 1-8	19.7	152
87	Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 19079-84	11.5	109
86	Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. *Nature Communications*, **2019**, 10, 3068	17.4	94
85	Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. *Immunity*, **2021**, 54, 1611-1621.e5	32.3	85
84	HIV prevention: Bring safe sex to China. *Nature*, **2012**, 485, 576-7	50.4	82
83	Antibodies and vaccines against Middle East respiratory syndrome coronavirus. *Emerging Microbes and Infections*, **2019**, 8, 841-856	18.9	58

82	Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. *Scientific Reports*, **2015**, 5, 13133	4.9	54
81	A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses. *Journal of Virology*, **2012**, 86, 2978-89	6.6	51
80	Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient. *Journal of Infectious Diseases*, **2018**, 218, 1249-1260	7	50
79	Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. *Journal of Biological Chemistry*, **2011**, 286, 14531-41	5.4	45
78	Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. *Nature Communications*, **2021**, 12, 250	17.4	45
77	Natural mutations in the receptor binding domain of spike glycoprotein determine the reactivity of cross-neutralization between palm civet coronavirus and severe acute respiratory syndrome coronavirus. *Journal of Virology*, **2007**, 81, 4694-700	6.6	44
76	Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein. *Cell Reports*, **2018**, 24, 441-452	10.6	43
75	Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. *Cell Host and Microbe*, **2021**, 29, 551-563.e5	23.4	42
74	In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. *Journal of Biological Chemistry*, **2011**, 286, 3277-87	5.4	41
73	Delineating antibody recognition against Zika virus during natural infection. *JCI Insight*, **2017**, 2,	9.9	41
72	A Dual-reporter system for real-time monitoring and high-throughput CRISPR/Cas9 library screening of the hepatitis C virus. *Scientific Reports*, **2015**, 5, 8865	4.9	39
71	Potent neutralizing monoclonal antibodies against Ebola virus infection. *Scientific Reports*, **2016**, 6, 25856	4.9	36
70	Genetic characterization of diverse HIV-1 strains in an immigrant population living in New York City. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2006**, 41, 399-404	3.1	36
69	Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody. *PLoS Pathogens*, **2016**, 12, e1005454	7.6	36
68	Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. *Journal of Virology*, **2013**, 87, 5669-77	6.6	33
67	A novel cell culture system modeling the SARS-CoV-2 life cycle. *PLoS Pathogens*, **2021**, 17, e1009439	7.6	33
66	Comprehensive analysis of antibody recognition in convalescent humans from highly pathogenic avian influenza H5N1 infection. *Nature Communications*, **2015**, 6, 8855	17.4	31
65	Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice. *Journal of Clinical Investigation*, **2018**, 128, 2239-2251	15.9	31

64	Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution. *Nature Communications*, **2021**, 12, 1607	17.4	31
63	Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection. *Emerging Microbes and Infections*, **2019**, 8, 760-772	18.9	30
62	Migration patterns of hepatitis C virus in China characterized for five major subtypes based on samples from 411 volunteer blood donors from 17 provinces and municipalities. *Journal of Virology*, **2014**, 88, 7120-9	6.6	27
61	The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes. *Journal of Virological Methods*, **2007**, 144, 17-26	2.6	26
60	DeepHINT: understanding HIV-1 integration via deep learning with attention. *Bioinformatics*, **2019**, 35, 1660-1667	7.2	26
59	A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01. *Journal of Biological Chemistry*, **2012**, 287, 43170-9	5.4	25
58	Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. *PLoS ONE*, **2011**, 6, e19863	3.7	25
57	MSM and HIV-1 infection in China. *National Science Review*, **2015**, 2, 388-391	10.8	24
56	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. *Nature Communications*, **2021**, 12, 4210	17.4	23
55	A Single Injection of Human Neutralizing Antibody Protects against Zika Virus Infection and Microcephaly in Developing Mouse Embryos. *Cell Reports*, **2018**, 23, 1424-1434	10.6	20
54	Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. *Cell Research*, **2021**, 31, 517-525	24.7	20
53	Forecasting influenza activity using self-adaptive AI model and multi-source data in Chongqing, China. *EBioMedicine*, **2019**, 47, 284-292	8.8	18
52	Unraveling of a neutralization mechanism by two human antibodies against conserved epitopes in the globular head of H5 hemagglutinin. *Journal of Virology*, **2013**, 87, 3571-7	6.6	18
51	Comprehensive analysis of pathogen-specific antibody response in vivo based on an antigen library displayed on surface of yeast. *Journal of Biological Chemistry*, **2011**, 286, 33511-9	5.4	18
50	Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays. *Emerging Microbes and Infections*, **2020**, 9, 2269-2277	18.9	18
49	Structural Basis for Neutralization and Protection by a Zika Virus-Specific Human Antibody. *Cell Reports*, **2019**, 26, 3360-3368.e5	10.6	15
48	Discovery of Imidazo[1,2-][1,8]naphthyridine Derivatives as Potential HCV Entry Inhibitor. *ACS Medicinal Chemistry Letters*, **2015**, 6, 977-81	4.3	15
47	Broadly neutralizing antibodies and vaccine design against HIV-1 infection. *Frontiers of Medicine*, **2020**, 14, 30-42	12	14

46	Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies. *PLoS Pathogens*, **2019**, 15, e1007819	7.8	12
45	A vaccine crisis in the era of social media. *National Science Review*, **2018**, 5, 8-10	10.8	12
44	A safety consideration of mesenchymal stem cell therapy on COVID-19. *Stem Cell Research*, **2020**, 49, 102066	1.6	12
43	Differential impact of non-pharmaceutical public health interventions on COVID-19 epidemics in the United States. *BMC Public Health*, **2021**, 21, 965	4.1	11
42	Discovery of New Hepatitis B Virus Capsid Assembly Modulators by an Optimal High-Throughput Cell-Based Assay. *ACS Infectious Diseases*, **2019**, 5, 778-787	5.5	10
41	Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses. *Journal of Biological Chemistry*, **2018**, 293, 830-846	5.4	10
40	Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization. *Molecules*, **2015**, 20, 10342-59	4.8	9
39	Open letter from Chinese HIV professionals on human genome editing. *Lancet, The*, **2019**, 393, 26-27	40	9
38	Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 5682-6	2.9	8
37	SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usage		8
36	A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation. *Cell Reports*, **2019**, 27, 2593-2607.e5	10.6	7
35	Development of a Potent and Protective Germline-Like Antibody Lineage Against Zika Virus in a Convalescent Human. *Frontiers in Immunology*, **2019**, 10, 2424	8.4	7
34	Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction.. *Cell Research*, **2022**,	24.7	7
33	Stabilized diverse HIV-1 envelope trimers for vaccine design. *Emerging Microbes and Infections*, **2020**, 9, 775-786	18.9	6
32	Complementary recognition of the receptor-binding site of highly pathogenic H5N1 influenza viruses by two human neutralizing antibodies. *Journal of Biological Chemistry*, **2018**, 293, 16503-16517	5.4	6
31	Digitalized Adaptation of Oncology Trials during and after COVID-19. *Cancer Cell*, **2020**, 38, 148-149	24.3	5
30	Spatiotemporal hierarchy in antibody recognition against transmitted HIV-1 envelope glycoprotein during natural infection. *Retrovirology*, **2016**, 13, 12	3.6	5
29	Both structure and function of human monoclonal antibodies contribute to enhancement of Zika virus infectivity in vitro. *Science China Life Sciences*, **2017**, 60, 1396-1398	8.5	5

28	A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants.. *Frontiers in Immunology*, **2021**, 12, 766821	8.4	5
27	Single-Dose Immunization With a Chimpanzee Adenovirus-Based Vaccine Induces Sustained and Protective Immunity Against SARS-CoV-2 Infection. *Frontiers in Immunology*, **2021**, 12, 697074	8.4	5
26	Structural and functional definition of a vulnerable site on the hemagglutinin of highly pathogenic avian influenza A virus H5N1. *Journal of Biological Chemistry*, **2019**, 294, 4290-4303	5.4	4
25	Combinatorial library-based profiling of the antibody response against hepatitis C virus in humans. *Journal of General Virology*, **2015**, 96, 52-63	4.9	4
24	Structural and computational insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction		4
23	A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus. *Nature Communications*, **2021**, 12, 6624	17.4	3
22	Broad-spectrum virucidal activity of bacterial secreted lipases against flaviviruses, SARS-CoV-2 and other enveloped viruses		3
21	Anonymous Linkage Between College Students and Human Immunodeficiency Virus (HIV) Facilities: Systematic Evaluation of Urine Self-Collection for HIV Testing Initiative in China. *Clinical Infectious Diseases*, **2021**, 73, e1108-e1115	11.6	3
20	Structural basis of severe acute respiratory syndrome coronavirus 2 infection. *Current Opinion in HIV and AIDS*, **2021**, 16, 74-81	4.2	3
19	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants.. *IScience*, **2022**, 104043	6.1	3
18	Persistence of VRC01-resistant HIV-1 during antiretroviral therapy. *Science China Life Sciences*, **2014** , 57, 88-96	8.5	2
17	Loss of Spike N370 glycosylation as an important evolutionary event for the enhanced infectivity of SARS-CoV-2.. *Cell Research*, **2022**,	24.7	2
16	A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates. *Cell Reports Medicine*, **2021**, 2, 100448	18	2
15	Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies		2
14	Role of efficient testing and contact tracing in mitigating the COVID-19 pandemic: a network modelling study. *BMJ Open*, **2021**, 11, e045886	3	2
13	Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection.. *Cell Discovery*, **2021**, 7, 123	22.3	2
12	Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses. *Vaccine*, **2017**, 35, 2582-2591	4.1	1
11	No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E5115	11.5	1

List of Publications

10	Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution		1
9	An integrated framework for modelling quantitative effects of entry restrictions and travel quarantine on importation risk of COVID-19. *Journal of Biomedical Informatics*, **2021**, 118, 103800	10.2	1
8	Surging publications on the COVID-19 pandemic. *Clinical Microbiology and Infection*, **2021**, 27, 484-486	9.5	1
7	Tandem bispecific antibody prevents pathogenic SHIV infection and disease progression. *Cell Reports*, **2021**, 36, 109611	10.6	1
6	Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization.. *Proceedings of the National Academy of Sciences of the United States of America*, **2022**, 119, e2122954119	11.5	1
5	Broadly neutralizing antibodies against SARS-CoV-2 variants **2022**, 1, 20220005		1
4	HLA-mismatched allogeneic adoptive immune therapy in severely immunosuppressed AIDS patients. *Signal Transduction and Targeted Therapy*, **2021**, 6, 174	21	0
3	Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques. *Vaccine*, **2021**, 39, 915-925	4.1	0
2	V4 region of the HIV-1 envelope gene mediates immune escape and may not promote the development of broadly neutralizing antibodies. *Vaccine*, **2018**, 36, 7700-7707	4.1	0
1	A commentary of Shock and Kill of Latent HIV in 10 remarkable discoveries from 2020 in Nature. *Fundamental Research*, **2022**,		